Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.35 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL632652 | 0.78 | KCNH2 (0.39) | CNR1CNR2KCNH2 | |
| SCHEMBL632992 | 0.69 | KCNH2 (0.33) | CNR1CNR2KCNH2CCR8 | |
| SCHEMBL3335199 | 0.69 | FERMT2 (0.53) | KCNH2 | |
| SCHEMBL5749369 | 0.68 | EGFR (0.39) | KCNH2 | |
| SCHEMBL3070145 | 0.67 | EGFR (0.39) | KCNH2 | |
| SCHEMBL3335196 | 0.66 | EHMT2 (0.46) | CNR1CNR2KCNH2 | |
| SCHEMBL10623577 | 0.66 | HTR2A (0.44) | KCNH2 | |
| SCHEMBL85215 | 0.66 | OPRM1 (0.44) | KCNH2SCN7ASCN5ASCN9A | |
| SCHEMBL1147498 | 0.66 | KCNH2 (0.43) | KCNH2 | |
| SCHEMBL13634243 | 0.65 | SCN9A (0.41) | KCNH2SCN7ASCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505750-B2 | 5-aminocyclylmethyl-oxazolidin-2-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-29 | — | — | US | disclosed |
| EP-2245028-B1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | CNKSR1, KCNH1, CBR3 | CNR1 205/4885CNR2 564/4885KCNH2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.